Protein Corona-Tailored Nanoplatform Boosts Tumor Accumulation and Reprograms Macrophages for Osteosarcoma Therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42084549.
- Also identified by DOI 10.1021/acs.nanolett.6c01040.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Osteosarcoma is featured with an immunosuppressive tumor microenvironment (TME) and limited therapeutic efficacy. Herein, we report a pH-responsive nanoplatform based on calcium phosphate (CaP)-coated Prussian blue nanoparticles (PB@CaP NPs) for optimized systemic delivery and antitumor immune response. The CaP interface inhibits the protein corona formation in blood, reducing complement-mediated clearance and prolonging circulation, and enhancing tumor accumulation of the nanoparticles. The pH-responsive dissolution of PB@CaP NPs enables the sequential release of calcium ions in the acidic TME and iron ions in lysosomes, together with the peroxidase-like catalytic activity of the PB core, establishing a synergistic ion/nanozyme signaling axis that triggers robust ROS generation and oxidative stress, thereby reprogramming tumor-associated macrophages from an immunosuppressive M2-like to a pro-inflammatory M1-like phenotype and remodeling the tumor immune microenvironment. This study provides a rational surface engineering strategy for nanoimmunotherapy.
Medical subject headings
- Osteosarcoma
- Nanoparticles
- Protein Corona
- Macrophages
- Bone Neoplasms